Advertisement.

PEPG Projected Dividend Yield

PepGen Incorporation ( NASDAQ : PEPG )

PepGen is a clinical-stage biotechnology company. Co.'s primary product candidate is PGN-EDO51, an Enhanced Delivery Oligonucleotide (EDO) peptide conjugated to a phosphorodiamidate morpholino oligomers (PMO) therapeutic cargo, which it is developing for the treatment of Duchenne muscular dystrophy (DMD) patients with mutations amenable to an exon 51-skipping approach. Co. is developing PGN-EDODM1, an EDO peptide-conjugated PMO, for the treatment of myotonic dystrophy type 1. Co.'s second EDO therapeutic candidate for the treatment of DMD, and third product candidate, PGN-EDO53, is an EDO peptide-conjugated PMO designed to skip exon 53 of the dystrophin transcript.

20 YEAR PERFORMANCE RESULTS

PEPG Dividend History Detail
PEPG Dividend News
PEPG Competitors News

# of Shares: 0

Closing Price: 4.68

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000